Screener
Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Revenue Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept mlab:CostOfRevenueOther.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
| Three months ended June 30, 2026 | Sterilization and Disinfection Control | Biopharmaceutical Development | Calibration Solutions | Clinical Genomics | Total |
|---|---|---|---|---|---|
| Less | |||||
| Depreciation in cost of revenue | 437 | 78 | 111 | 119 | 745 |
| Amortization in cost of revenue | 121 | 379 | - | 191 | 691 |
| Other cost of revenue (b) | 6,788 | 4,020 | 5,143 | 3,739 | 19,690 |
| Total segment cost of revenue | 7,346 | 4,477 | 5,254 | 4,049 | 21,126 |
| Gross Profit (c) | $17,159 | $7,582 | $8,031 | $6,240 | $39,012 |
| Reconciling items: | |||||
| Operating expense | $31,981 |
Document
FAQ
- What is Mesa Laboratories's biopharmaceutical development — cost of revenue other?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of revenue other of $4.02M in Q2 2026.
- How has Mesa Laboratories's biopharmaceutical development — cost of revenue other changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — cost of revenue other decreased by 14.8% year-over-year, from $4.72M to $4.02M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of revenue other?
- Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of revenue other has grown at a 15.2% compound annual growth rate (CAGR), from $13.75M to $18.25M.
- What does biopharmaceutical development — cost of revenue other mean?
- Includes all direct costs associated with generating revenue in the Biopharmaceutical Development segment that are not classified as depreciation or amortization. This typically encompasses direct labor, raw materials, and overhead costs directly linked to the production of goods or delivery of services. It provides insight into the variable cost structure of the segment's core operations.
Ask your AI about Mesa Laboratories's biopharmaceutical development — cost of revenue other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude